Zhejiang Haichang Biopharma Ranks Among China's Top 30 Most Innovative New Technology Drug Companies
Haichang Biotech
Innovative Formulation Developer
6Month25Day, held in Huzhou, Zhejiang, China2024At the Misi Conference, Zhejiang Haichang Biotech Co., Ltd. successfully ranked among the "Top Innovative Chinese New Technology Drug Companies" due to its outstanding innovation and strong R&D capabilities in the field of new technology drug development.TOP30"Ranking List."This honor is not only a high recognition of Haichang Biotech's innovative R&D capabilities, but also a strong proof of its market competitiveness, demonstrating the company's outstanding strength in the field of new drug development.
The selection activity for the "Top 100 List of Innovative Chinese Biomedical Enterprises in 2023" was hosted by Menet, with the evaluation cycle covering the entire year of 2023. Based on the "Enterprise Innovation Capability Evaluation Index System" from the Ministry of Science and Technology, and combined with the characteristics of China's biomedical industry, an evaluation system for innovation capability of Chinese biomedical enterprises was constructed, focusing on four major dimensions - "innovation investment", "innovation output", "intellectual property", and "innovation-driven" - along with eleven indicators.
As a leader in the field of new drug development, Haichang Biotech has been committed to promoting the steady, rapid, and sustainable development of the pharmaceutical and healthcare industry. This listing is not only an affirmation of its past efforts but also an expectation for its future development. Haichang Biotech will continue to uphold the spirit of innovation, increase R&D investment, continuously enhance its R&D capabilities and market competitiveness, and contribute more to the development of the pharmaceutical and healthcare industry.
Haichang Biotech, located in China Medical Valley, Hangzhou, is a national high-tech enterprise with a focus on innovative biopharmaceutical technology development, possessing independent innovation capabilities and global intellectual property rights. The company adheres to its core values of "sharing, progress, truth-seeking, and pragmatism," with a focus on the development and industrialization of drug delivery systems. It specializes in the development of nucleic acid innovative drugs such as mRNA vaccines and small nucleic acid drugs, as well as advanced complex injectables. Currently, albumin paclitaxel has been approved for marketing in China and is under registration review in the EU and other countries. The innovative drug HC0301 has received approval from the FDA and NMPA to conduct multicenter Phase II clinical trials. The product pipeline covers areas including infectious disease prevention, tumor immunotherapy, anti-tumor treatments, and pain management.
